Intravenous Transplantation of an Ischemic-specific Peptide-TPP-mitochondrial Compound Alleviates Myocardial Ischemic Reperfusion Injury
ACS Nano · 2023-01-24 · 17 (2) · 896-909
DOI: 10.1021/acsnano.2c05286 ↗At a glance
Journal article in ACS Nano, published online on 2023-01-10. Written by Xiaolei Sun and 12 co-authors. Institution: Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China. Cited 122 times so far (Crossref); 38 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: National Natural Science Foundation of China, Top Hospital and Specialty Excellence of Fujian Province.
Abstract (original language)
It is known that mitochondrial dysfunction is a critical factor involved in myocardial ischemia-reperfusion injury. Mitochondrial transplantation has been suggested as an effective therapeutic strategy to protect against myocardial ischemia-reperfusion injury. However, its clinical translation remains limited because it requires the local injection of mitochondria into the myocardium. Here, a polypeptide, CSTSMLKAC (PEP), bound to triphenylphosphonium cations (TPP+) effectively binds mitochondria to form a PEP-TPP-mitochondrial compound. Further investigation of this compound has revealed that the ischemia-sensing properties of PEP promote its translocation into the ischemic myocardium. Additionally, the targeting peptide, PEP, readily dissociates from the PEP-TPP-mitochondrial compound, allowing for the transplanted mitochondria to be efficiently internalized by cardiomyocytes or transferred to cardiomyocytes by endothelial cells. Mitochondrial transplantation promotes cardiomyocyte energetics and mechanical contraction, subsequently reducing cellular apoptosis, macrophage infiltration, and the pro-inflammatory response, all of which lead to attenuation of ischemia-reperfusion injury. Thus, this study provides promising evidence that the PEP-TPP-mitochondrial compound effectively promotes intravenous mitochondrial transplantation into the ischemic myocardium and subsequently ameliorates myocardial ischemia-reperfusion injury.
Subjects
Author keywords
Authors and institutions
- Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China.
- Shanghai Institute of Cardiovascular Diseases, Shanghai 200032, P.R. China.
- NHC Key Laboratory of Viral Heart Diseases, Shanghai 200032, P.R. China.
- Key Laboratory of Viral Heart Diseases, Chinese Academy of Medical Sciences, Shanghai 200032, P.R. China.
- Cardiac Regeneration and Ageing Lab, Institute of Cardiovascular Sciences, Shanghai Engineering Research Center of Organ Repair, School of Life Science, Shanghai University, Shanghai 200444, P.R. China.
- Shanghai Fifth People's Hospital, Fudan University, Shanghai 200240, P.R. China.
ORCID profiles: Xiaolei Sun, Ning Zhang
Funding
- National Natural Science Foundation of China
- Top Hospital and Specialty Excellence of Fujian Province
Cite
APA
Sun, X., Chen, H., Gao, R., Qu, Y., Huang, Y., Zhang, N., Hu, S., Fan, F., Zou, Y., Hu, K., Chen, Z., Ge, J., & Sun, A. (2023). Intravenous Transplantation of an Ischemic-specific Peptide-TPP-mitochondrial Compound Alleviates Myocardial Ischemic Reperfusion Injury. ACS Nano, 17(2), 896-909. https://doi.org/10.1021/acsnano.2c05286
Vancouver
Sun X, Chen H, Gao R, Qu Y, Huang Y, Zhang N, et al. Intravenous Transplantation of an Ischemic-specific Peptide-TPP-mitochondrial Compound Alleviates Myocardial Ischemic Reperfusion Injury. ACS Nano. 2023;17(2):896-909. doi:10.1021/acsnano.2c05286
BibTeX
@article{Sun2023,
author = {Sun, Xiaolei and Chen, Hang and Gao, Rifeng and Qu, Yanan and Huang, Ya and Zhang, Ning and Hu, Shiyu and Fan, Fan and Zou, Yunzeng and Hu, Kai and Chen, Zhaoyang and Ge, Junbo and Sun, Aijun},
title = {Intravenous Transplantation of an Ischemic-specific Peptide-TPP-mitochondrial Compound Alleviates Myocardial Ischemic Reperfusion Injury},
journal = {ACS Nano},
year = {2023},
volume = {17},
number = {2},
pages = {896--909},
doi = {10.1021/acsnano.2c05286}
}
EUVIMED